According to my CEO friend in the bio pharma industry, they could also have told you a fib. He has never heard of a placeholder abstract, as conferences would never accept such a thing. The abstract submitted have to be certain enough for them to accept it. If they didn't have demands for the level of abstract submitted, every bio pharma company would submit to every conference, just in case.
They might have meant it as a placeholder, but they probably had to submit enough of an abstract to get admitted to the conference. These conferences have deadline to withdraw, and in the case of SITC, it was Oct. 15.
Please don't misunderstand me, but DI can pretty much tell you anything in a phone call without any legal consequence.
I am sure you are right and this is what has actually transpired, but I wouldn't be surprised to see a different tone Monday morning. It doesn't really matter as the market is currently closed and if SITC does publish whatever they submitted, Company would know it in time to send out a PR Monday morning.
I will only post what I have been told by those with experience in this industry. I will not engage in speculations without clearly stating that it is just my opinion. I think anything else is irresponsible.
GLTA and patients.
News 
Market Data 
Discover 
